Core One Labs Enters Into LOI For First Sale Of Its Psychedelic Compounds
Core One Labs Enters Into LOI For First Sale Of Its Psychedelic Compounds
GMP Drug Inc., a wholly-owned subsidiary of Core One Labs Inc. (OTCQB:CLABF) (CSE:COOL)(Frankfurt:LD6) (WKN: A3CSSU) has entered into a non-binding letter of intent with Zollaris Laboratories Corporation, an arms-length party, in pursuit of a potential transaction involving the sale by GMP Drug of psychedelic compounds including but not limited to biosynthetic psilocybin, psilocin, DMT formulated by Vocan Biotechnologies Inc. and Awakened Biosciences Inc., each also wholly-owned subsidiaries of Core One.
GMP藥品公司，一家全資子公司Core One實驗室公司(OTCQB：CLABF)(CSE：COOL)(法蘭克福：LD6)(WKN：A3CSSU)與Zollaris實驗室公司簽訂了一份不具約束力的意向書，一個保持距離的一方，尋求一項涉及銷售按GMP藥品分類迷幻化合物，包括但不限於生物合成的裸蓋菇素、裸蓋菇素、DMT制定者：Vocan BioTechnologies Inc.和覺醒的生物科學公司。，每一家都是Core One的全資子公司。
Zollaris is a licensed pharmaceutical company that currently holds a license to possess, and conduct laboratory analysis on, psilocybin. The LOI proposes that GMP Drug will enter an arrangement in which Awakened and Vocan will formulate and GMP Drug will supply proprietary psychedelics produced using the patent-pending production methods of Awakened and Vocan, to Zollaris, pursuant to a definitive agreement, the terms of which are currently under negotiation. It is anticipated that the proprietary psychedelic compounds will be supplied to Zollaris at an agreed upon cost per gram, and in amounts requested by Zollaris.
Zollaris是一家有執照的製藥公司，目前持有擁有裸蓋菇素並對其進行實驗室分析的許可證。意向書建議，根據一項最終協定，GMP藥品公司將進入一項安排，其中覺醒和Vocan公司將配製，GMP藥物公司將向Zollaris公司提供使用正在申請專利的WAKENED和Vocan生產方法生產的專有迷幻劑，該協定的條款目前正在談判中。預計專有迷幻化合物將以商定的每克成本和Zollaris要求的數量供應給Zollaris。
The definitive agreement is anticipated to incorporate the principal terms set forth in the LOI and, in addition, such other terms and provisions of a more detailed nature as the parties may agree upon and as are customary for transactions of this nature. The consummation of the final supply arrangement is subject to a number of conditions, including the satisfaction of each party's respective due diligence, the negotiation and execution of the definitive agreement and Zollaris holding a valid controlled substances license from Health Canada permitting the acquisition and possession of psilocybin.
最終協定預計將包括《意向書》中規定的主要條款，以及各方可能商定的更詳細性質的其他條款和規定，這是此類交易的慣例。最終供應安排的完成取決於若干條件，包括各方是否滿足各自的盡職調查、最終協定的談判和執行以及Zollaris持有加拿大衛生部的有效受控物質許可證，允許收購和擁有裸蓋菇素。
Photo: Benzinga edit with photos by geralt and sergeitokmakov on Pixabay
圖片：Benzinga編輯與Geralt和Sergeitokmakov在Pixabay上的照片
Benzinga Cannabis Capital Conference
本辛加大麻首都會議
The Benzinga Cannabis Capital Conference, the place where deals get done, is returning to Chicago this Sept 27-28 for its 17th edition. Get your tickets today before prices increase and secure a spot at the epicenter of cannabis investment and branding.
Benzinga Cannabis Capital Conference是達成交易的地方，將於今年9月27日至28日返回芝加哥舉行第17屆。在價格上漲之前今天就買到票，並在大麻投資和品牌推廣的中心獲得一席之地。
Related News
相關新聞
Core One In Talks With Multiple Companies To Supply Psilocybin
核心一號正在與多家公司洽談供應裸蓋菇素
譯文內容由第三人軟體翻譯。